Search

Your search keyword '"Troya, Jesús"' showing total 208 results

Search Constraints

Start Over You searched for: Author "Troya, Jesús" Remove constraint Author: "Troya, Jesús"
208 results on '"Troya, Jesús"'

Search Results

2. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

6. Epigenome-wide association study of COVID-19 severity with respiratory failure

8. Real-life data of immune recovery using bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48–96 weeks of RETROBIC Study

12. 1571. BIC/FTC/TAF in Virologically Suppressed PLWHIV: 48-96 weeks RETROBIC Multicenter Cohort study results.

14. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

17. Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens

18. Epidemiological and Clinical Characteristics of Patients Admitted to a Secondary Hospital with Suspected MPOX Virus Infection: Is HIV Playing a Role?

20. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV

21. Myocardial Work Index in Professional Football Players: A Novel Method for Assessment of Cardiac Adaptation

22. Predict the Effects of Dolutegravir (DTG) Plus Lamivudine (3TC) on Immunological Responses in People Living with HIV (PLWHIV)

23. Predict the effects of dolutegravir (DTG) plus lamivudine (3TC) on immunological responses in people living with HIV (PLWHIV)

24. Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens

27. Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic

28. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

29. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

30. 1262. Dolutegravir Plus 3TC In Antiretroviral Experienced Adults: Immunovirological Outcomes In a Multicenter Retrospective Cohort In Spain

33. Dolutegravir plus rilpivirine: benefits beyond viral suppression

34. The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies

35. HCV eradication with DAAs differently affects HIV males and females: A whole miRNA sequencing characterization

36. HCV eradication with DAAs differently affects HIV males and females: A whole miRNA sequencing characterization

37. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19

39. Effectiveness of an HIV care model integrated into addiction care based on medication-assisted treatment for HIV-positive people who use drugs.

41. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19.

42. HCV eradication with DAAs differently affects HIV males and females: A whole miRNA sequencing characterization

43. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19

44. Epigenome-wide association study of COVID-19 severity with respiratory failure

47. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naïve Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)

48. Characteristics, complications and outcomes among 1549 patients hospitalised with COVID-19 in a secondary hospital in Madrid, Spain: a retrospective case series study

49. Comparison of Noninvasive Cardiac Test Strategies for Newly Diagnosed Chagas Disease in a Non-Endemic Zone

Catalog

Books, media, physical & digital resources